Episode
Episode 497: Reflections on the capivasertib ODAC
- Podcast
- The Uromigos
- Published
- May 1, 2026
- Duration seconds
- 1275
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-497-Reflections-on-the-capivasertib-ODAC-e3ip0uq
Actions
POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-497-reflections-on-the-capivasertib-odac/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-uromigos-1214845/episode-497-reflections-on-the-capivasertib-odac.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.